Supplementary Figure 1: Madcam1 expressions in HCC tissues and HCC cells under different treatment (A-B) Doxorubicin reduced Madcam1 expression. SMMC-7721 and Bel-7402 cells were treated with DMSO and increasing concentration of Doxo (final concentration 0.5-2.0 g/ml) for 24 h before harvest for WB analysis. The representative images of WB are shown in panel A, and the relative expression
levels of Madcam1 were calculated as the ratio to GAPDH, and the data are shown in the panel B. The "DMSO" group was arbitrarily set to 100 %.
(C) CHX chase analysis of proteins as indicated. Bel-7402 cells were treated with CHX (final concentration 50 μg/ml) for indicated time before harvest for detecting proteins as indicated using WB analysis.
(D) Representative IHC images of Normal liver (n=5) and HCC tissues (n=24) stained using anti-Madcam1 antibodies. Enlarged Image of HCC#3 is shown in the bottom. Scale bar, 150 M.
Data are shown as Mean + SD from three independent experiments (including WB). **, p<0.01 using student t test. Figure   3E were calculated as the ratio to GAPDH. The data from "DMSO" groups were arbitrarily set to 100 %.
Supplementary Figure 2: Madcam1 had no influence on

Doxorubicin-induced effects in hepatocytes
(B) Knockdown of Madcam1 inhibited protein expression. Relative expression levels of proteins as indicated in Figure 3F in Bel-7402 cells were calculated as the ratio to GAPDH. The data from "GFP-sh" groups were arbitrarily set to 100 %.
(C) Doxo did not inhibit protein stability. Relative protein levels as indicated were normalized to that of GAPDH in Bel-7402 cells under same treatment in Figure 3I . The data from "DMSO/CHX 0h" and "Doxo/CHX 0h" were arbitrarily set to 100 %.
(D) Madcam1 did not stimulate protein stability. Relative protein levels as indicated were normalized to that of GAPDH in Bel-7402 cells under same treatment in Figure 3J . The data from "Empty/CHX 0h" and "Madcam1-Myc/CHX 0h" were arbitrarily set to 100 %. (p-4EBP1) were normalized to those from total 4EBP1. The data from the "DMSO" group were arbitrarily set to 100%.
(B) Madcam1 overexpression induced phosphorylation of 4EBP1. The treatments to Bel-7402 cells were the same as Figure 4C . Protein levels of the phosphorylated 4EBP1 (p-4EBP1) were normalized to those from total 4EBP1. The data from the "Empty" group were arbitrarily set to 100%.
(C) Madcam1 knockdown reduced phosphorylation of 4EBP1. The treatments to Bel-7402 cells were the same as Figure 4D . Protein levels of the phosphorylated 4EBP1 (p-4EBP1) were normalized to those from total 4EBP1. The data from the "GFP-sh" group was arbitrarily set to 100%.
(D) Madcam1 reversed Doxo-induced de-phosphorylation of 4EBP1. The treatments to Bel-7402 cells were the same as Figure 4H . Protein levels of the phosphorylated 4EBP1 (p-4EBP1) were normalized to those from total 4EBP1. The data from "Mock (untreated)" group were arbitrarily set to 100%.
(E) Madcam1 prevented protein down-regulation by Doxo. Levels of the indicated proteins in Figure 4I were normalized to those of GAPDH. The data from the "Mock (untreated)" group were arbitrarily set to 100%.
Data are shown as Mean + SD from three independent experiments (including WB). **, p<0.01 using student t test.
